Search research articles
Contact Us
Filters
Showing results (1-10 of 181) with videos related to
Page
of 19
Sort By:
Anti-Cancer Drugs
|
August 21, 2002
Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia
Ioannis A Voutsadakis
Euroasian Journal of Hepato-Gastroenterology
|
January 29, 2021
A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Ioannis A Voutsadakis
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
January 12, 2022
Biomarkers of everolimus efficacy in breast cancer therapy
Ioannis A Voutsadakis
Clinical Colorectal Cancer
|
March 21, 2021
The Landscape of PIK3CA Mutations in Colorectal Cancer
Ioannis A Voutsadakis
World Journal of Gastrointestinal Oncology
|
November 24, 2011
Molecular predictors of gemcitabine response in pancreatic cancer
Ioannis A Voutsadakis
Medicina (Kaunas, Lithuania)
|
September 28, 2021
Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer
Ioannis A Voutsadakis
Current Oncology (Toronto, Ont.)
|
March 24, 2022
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
Ioannis A Voutsadakis
World Journal of Gastrointestinal Oncology
|
December 17, 2010
Peroxisome proliferator activated receptor-γ and the ubiquitin-proteasome system in colorectal cancer
Ioannis A Voutsadakis
Annals of Translational Medicine
|
April 21, 2020
A role for Follistatin-like protein 1 (FSTL1) in colorectal cancer
Ioannis A Voutsadakis
Diabetes & Metabolic Syndrome
|
December 20, 2016
Obesity and diabetes as prognostic factors in patients with colorectal cancer
Ioannis A Voutsadakis
Page
of 19
Search research articles
Search
Showing results (1-10 of 181) with videos related to
Sort By:
Page
of 19
Anti-Cancer Drugs
|
August 21, 2002
Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia
Ioannis A Voutsadakis
Euroasian Journal of Hepato-Gastroenterology
|
January 29, 2021
A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Ioannis A Voutsadakis
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
January 12, 2022
Biomarkers of everolimus efficacy in breast cancer therapy
Ioannis A Voutsadakis
Clinical Colorectal Cancer
|
March 21, 2021
The Landscape of PIK3CA Mutations in Colorectal Cancer
Ioannis A Voutsadakis
World Journal of Gastrointestinal Oncology
|
November 24, 2011
Molecular predictors of gemcitabine response in pancreatic cancer
Ioannis A Voutsadakis
Medicina (Kaunas, Lithuania)
|
September 28, 2021
Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer
Ioannis A Voutsadakis
Current Oncology (Toronto, Ont.)
|
March 24, 2022
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
Ioannis A Voutsadakis
World Journal of Gastrointestinal Oncology
|
December 17, 2010
Peroxisome proliferator activated receptor-γ and the ubiquitin-proteasome system in colorectal cancer
Ioannis A Voutsadakis
Annals of Translational Medicine
|
April 21, 2020
A role for Follistatin-like protein 1 (FSTL1) in colorectal cancer
Ioannis A Voutsadakis
Diabetes & Metabolic Syndrome
|
December 20, 2016
Obesity and diabetes as prognostic factors in patients with colorectal cancer
Ioannis A Voutsadakis
Page
of 19